Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metastasis Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CRK/c-Crk drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human CRK/c-Crk (Full Length / SH2-SH3 Domains) High purity (>95%), Endotoxin controlled. Sequence Verified. |
View CRK Products |
| Gene Delivery | CRK Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression. |
View CRK Products |
| Benchmark Ab | Anti-CRK Recombinant Antibody High-specificity clone for Western Blot, IP, and IHC control. |
View CRK Products |
| Validator | CRK siRNA Set Target-specific knockdown pool for functional assay validation. |
View CRK Products |
| Related Target A | CRKL (Crk-Like Proto-Oncogene) Highly homologous adapter protein; critical for off-target and selectivity screening. |
View CRKL Products |
| Related Target B | BCAR1 (p130Cas) Primary upstream binding partner of CRK SH2 domain; essential for focal adhesion signaling assays. |
View BCAR1 Products |
| Related Target C | PTK2 (FAK) Focal Adhesion Kinase; upstream regulator of the Cas/Crk signaling scaffold. |
View PTK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against CRKL homolog | Recombinant CRK and CRKL proteins strictly verified by Mass Spectrometry and sequence analysis. |
| Protein-Protein Interaction (PPI) disruption assay | Truncated SH2 and SH3 domain-specific proteins available with theoretical MW verification for precise assay setup. |
| Lack of reliable positive controls | Sequence-verified benchmark antibodies and validated siRNA sets included in the ecosystem. |
| Conformational cell-based validation | High-titer Lentivirus for stable cell lines to study real-time focal adhesion dynamics. |
Live CRK/c-Crk R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CRK/c-Crk therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum tyrosine kinase inhibitors to precise Protein-Protein Interaction (PPI) disruptors and targeted protein degradation (PROTACs). As first-generation adapter protein inhibitors reach preclinical milestones, the next wave of R& R&D is targeting the prevention of cancer metastasis and overcoming resistance to EGFR/ALK inhibitors in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic/Biotech Consortia | Glioblastoma, Non-Small Cell Lung Cancer (NSCLC) | High-purity SH2/SH3 domain proteins for SPR/FP competitive binding assays. |
| PROTACs / Degraders | Targeted Therapeutics Developers | Metastatic Breast Cancer, Melanoma | Full-length native-state CRK proteins for ternary complex formation assays. |
| RNA Therapeutics (siRNA/ASO) | Oligonucleotide Therapeutics Biotechs | Advanced Epithelial Cancers | Lentivirus-driven overexpression and validated siRNA tools for knockdown comparison. |